Please note the following on from information provided to NICE by the company in November 2013, the appraisal of Denosumab for preventing bone metastases in castrate resistant prostate cancer [ID405] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 405 |
| Referral date | 01 November 2011 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Communications manager: | Alice Law |
| Executive Lead: | TBC |
| Project manager: | |
| Technical Lead: | Richard Diaz |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 January 2023 | Discontinued. Please note the following on from information provided to NICE by the company in November 2013, the appraisal of Denosumab for preventing bone metastases in castrate resistant prostate cancer [ID405] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 28 November 2013 |
The Institute has now been informed by the manufacturer that it will no longer be pursuing a licensing application for denosumab in this indication, therefore, NICE has decided to suspend this appraisal on its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. |
| 17 April 2013 | The manufacturer of Denosumab has informed NICE that they will not provide a submission for this appraisal. NICE has therefore suspended this appraisal. |
For further information on our processes and methods, please see our CHTE processes and methods manual